Page 45 - Ovarian Cancer Surgery - Quality Indicators

178. Kumpulainen, S., et al. The effect of
hospital operative volume, residual tumor
and first-line chemotherapy on survival of
ovarian cancer - a prospective nation-wide 187. Deo, S.V., et al. Neoadjuvant
study in Finland. Gynecol Oncol 115, 199-
203 2009.
179. Ayhan, A., et al. The role of secondary
cytoreduction in the treatment of ovarian
cancer: Hacettepe University experience.
Am J Obstet Gynecol 194, 49-56 2006.
180. Bachmann, R., et al. The Prognostic Role
of Optimal Cytoreduction in Advanced,
Bowel Infiltrating Ovarian Cancer. J
Invest Surg 2015.
181. Di Giorgio, A., et al. Cytoreductive
surgery peritonectomy procedures
combined with hyperthermic
intraperitoneal chemotherapy HIPEC in
the treatment of diffuse peritoneal
carcinomatosis from ovarian cancer.
Cancer 113, 315-325 2008.
182. Lydiksen, L., Jensen-Fangel, S. &
Blaakaer, J. Is it possible to define an
optimal time for chemotherapy after
surgery for ovarian cancer? Gynecol Oncol
133, 454-459 2014.
183. Marth, C., et al. Influence of department
volume on survival for ovarian cancer:
results from a prospective quality
assurance program of the Austrian
Association for Gynecologic Oncology. Int
J Gynecol Cancer 19, 94-102 2009.
184. Rutten, M.J., et al. Prognostic Value of
Residual Disease after Interval Debulking
Surgery for FIGO Stage IIIC and IV
Epithelial Ovarian Cancer. Obstet Gynecol
Int 2015, 464123 2015.
185. Kang, S. & Nam, B.H. Does neoadjuvant
chemotherapy increase optimal
cytoreduction rate in advanced ovarian
cancer? Meta-analysis of 21 studies. Ann
Surg Oncol 16, 2315-2320 2009.
186. Lee, S.J., et al. Preliminary results of
neoadjuvant chemotherapy with paclitaxel
and cisplatin in patients with advanced
epithelial ovarian cancer who are
 OVARIAN CANCER SURGERY - QUALITY INDICATORS 
45
inadequate for optimum primary surgery. J
Obstet Gynaecol Res 32, 99-106 2006.
chemotherapy followed by surgical
cytoreduction in advanced epithelial
ovarian cancer. Indian J Cancer 43, 117-
121 2006.
188. Inciura, A., et al. Comparison of adjuvant
and neoadjuvant chemotherapy in the
management of advanced ovarian cancer: a
retrospective study of 574 patients. BMC
Cancer 6, 153 2006.
189. Steed, H., et al. A retrospective analysis of
neoadjuvant platinum-based chemotherapy
versus up-front surgery in advanced
ovarian cancer. Int J Gynecol Cancer 16
Suppl 1, 47-53 2006.
190. Hou, J.Y., et al. Neoadjuvant
chemotherapy lessens surgical morbidity
in advanced ovarian cancer and leads to
improved survival in stage IV disease.
Gynecol Oncol 105, 211-217 2007.
191. Colombo, P.E., et al. Aggressive surgical
strategies in advanced ovarian cancer: a
monocentric study of 203 stage IIIC and
IV patients. Eur J Surg Oncol 35, 135-143
2009.
192. Jacob, J.H., et al. Neoadjuvant
chemotherapy and interval debulking for
advanced epithelial ovarian cancer.
Gynecol Oncol 42, 146-150 1991.
193. Lim, J.T. & Green, J.A. Neoadjuvant
carboplatin and ifosfamide chemotherapy
for inoperable FIGO stage III and IV
ovarian carcinoma. Clin Oncol R Coll
Radiol) 5, 198-202 1993.
194. Schwartz, P.E., Rutherford, T.J.,
Chambers, J.T., Kohorn, E.I. & Thiel, R.P.
Neoadjuvant chemotherapy for advanced
ovarian cancer: long-term survival.
Gynecol Oncol 72, 93-99 1999.
195. Kayikcioglu, F., Kose, M.F., Boran, N.,
Caliskan, E. & Tulunay, G. Neoadjuvant
chemotherapy or primary surgery in
advanced epithelial ovarian carcinoma. Int
J Gynecol Cancer 11, 466-470 2001.